| Literature DB >> 25098612 |
Geoffroy Vanbiervliet1, Bertrand Napoléon2, Marie Christine Saint Paul3, Charlotte Sakarovitch4, Marc Wangermez5, Philippe Bichard6, Clément Subtil7, Stéphane Koch8, Philippe Grandval9, Rodica Gincul10, David Karsenti11, Laurent Heyries12, Jean-Christophe Duchmann13, Jean François Bourgaux14, Michaël Levy15, Gilles Calament16, Fabien Fumex2, Bertrand Pujol2, Christine Lefort2, Laurent Poincloux17, Maël Pagenault18, Eduardo Aimé Bonin19, Monique Fabre20, Marc Barthet19.
Abstract
BACKGROUND AND STUDY AIMS: A new core biopsy needle for endoscopic ultrasound (EUS)-guided sampling has recently been developed. The aim of this prospective multicenter study was to compare this needle with a standard needle in patients with solid pancreatic masses. PATIENTS AND METHODS: Consecutive patients with solid pancreatic masses referred to 17 centers for EUS-guided sampling were included. Each patient had two passes with a standard 22G needle and a single pass with a 22G core needle performed in a randomized order. Samples from both needles were separately processed for liquid-based cytology and cell-block preparation and were assessed independently by two blinded expert pathologists. The primary endpoint was the accuracy of the detection of malignancy. The reference standard was based on further cytohistological analysis obtained under ultrasound or computed tomography scanning, endoscopic or surgical guidance, and/or by clinical follow-up with repeated imaging examinations for at least 12 months. The secondary endpoints were the rate of technical failure and the quality of the cytohistological samples obtained.Entities:
Mesh:
Year: 2014 PMID: 25098612 DOI: 10.1055/s-0034-1377559
Source DB: PubMed Journal: Endoscopy ISSN: 0013-726X Impact factor: 10.093